Literature DB >> 22261470

Innate immunity and the etiology of late-onset Alzheimer's disease.

Piet Eikelenboom1, Erik van Exel, Rob Veerhuis, Annemieke J M Rozemuller, Willem A van Gool, Jeroen J M Hoozemans.   

Abstract

BACKGROUND: Neuropathological studies supported by experimental animal studies show that the constituents of the innate immunity are intimately involved in the early steps of the pathological cascade of Alzheimer's disease (AD).
OBJECTIVES: To show the evidence that constituents of the innate immunity contribute to the etiology of late-onset AD.
METHODS: Evaluation of the relationship between the constituents of the innate immunity and genetic risk factors for late-onset AD.
RESULTS: Complement activation and activated microglia are early neuropathogical events in AD brains. Genome-wide association studies have demonstrated gene loci that are linked to the complement system. The production capacity for inflammatory cytokines is under genetic control and the offspring with a parental history of late-onset AD have a higher production capacity for inflammatory cytokines.
CONCLUSION: Epidemiological and genetic data suggest that the innate immunity is involved in the etiology of late-onset AD.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261470     DOI: 10.1159/000334287

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  13 in total

Review 1.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Authors:  Luigi Ferrucci; Elisa Fabbri
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

2.  Are inflammatory profiles the key to personalized Alzheimer's treatment?

Authors:  Holly M Brothers; Donna M Wilcock
Journal:  Neurodegener Dis Manag       Date:  2013

Review 3.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

4.  High Aβ load may cause microglial cell dysfunction and reduced nuclear repressor element-1 silencing transcription factor (REST) expression which might be ascribed to its degradation by ubiquitination.

Authors:  Min Fang; Yanxin Zhao; Xueyuan Liu
Journal:  Ann Transl Med       Date:  2019-07

5.  What does complement do in Alzheimer's disease? Old molecules with new insights.

Authors:  Yong Shen; Libang Yang; Rena Li
Journal:  Transl Neurodegener       Date:  2013-10-12       Impact factor: 8.014

6.  Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss.

Authors:  Michael X Hernandez; Shan Jiang; Tracy A Cole; Shu-Hui Chu; Maria I Fonseca; Melody J Fang; Lindsay A Hohsfield; Maria D Torres; Kim N Green; Rick A Wetsel; Ali Mortazavi; Andrea J Tenner
Journal:  Mol Neurodegener       Date:  2017-09-18       Impact factor: 14.195

7.  Cell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.

Authors:  Yuichiro Itoh; Rhonda R Voskuhl
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

8.  Mannose-binding lectin inhibits monocyte proliferation through transforming growth factor-β1 and p38 signaling pathways.

Authors:  Yan Wang; A-De Chen; Yan-Mei Lei; Gui-Qiu Shan; Li-Yun Zhang; Xiao Lu; Zheng-Liang Chen
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

Review 9.  Inflammation: Bridging Age, Menopause and APOEε4 Genotype to Alzheimer's Disease.

Authors:  Aarti Mishra; Roberta D Brinton
Journal:  Front Aging Neurosci       Date:  2018-10-09       Impact factor: 5.750

10.  Microglia, Alzheimer's disease, and complement.

Authors:  Helen Crehan; John Hardy; Jennifer Pocock
Journal:  Int J Alzheimers Dis       Date:  2012-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.